Clinical Trials Logo

MZL clinical trials

View clinical trials related to MZL.

Filter by:
  • None
  • Page 1

NCT ID: NCT05176691 Withdrawn - Follicular Lymphoma Clinical Trials

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Start date: February 15, 2022
Phase: Phase 1
Study type: Interventional

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL

NCT ID: NCT03846427 Completed - Clinical trials for Marginal Zone Lymphoma

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

MAGNOLIA
Start date: February 19, 2019
Phase: Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).

NCT ID: NCT03797456 Completed - MZL Clinical Trials

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 110 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.